Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00120172
Recruitment Status :
(positive results from a larger study with same regimen was released.)
Currently there is no one standard of care for older patients with metastatic colorectal cancer. The study will examine the tumor response to capecitabine, oxaliplatin, plus bevacizumab. The study will also gather information on the usefulness and side effects of this treatment combination.
Condition or disease
Colorectal CancerNeoplasm Metastasis
Drug: oxaliplatin, capecitabine, bevacizumab
Colorectal cancer is primarily a disease of the elderly, with the median age in the United States of 70 years. Age greater than 65 years at presentation is not a contraindication to standard therapies; acceptable morbidity and mortality, as well as long term survival, are achieved in this patient population. However, studies evaluating combination therapy have generally involved younger patients with high performance status scores. Given the non-over-lapping safety profiles of the proposed study agents and the potential synergy, it would be of benefit to explore the combination of oxaliplatin, capecitabine, and bevacizumab in the treatment of older patients with colorectal cancer. Time to progression, overall response, duration of response, and toxicity profile will be evaluated. The feasibility of using a self-report geriatric assessment tool will also be assessed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
65 Years and older (Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age 65 years and above;
Histologically or cytologically documented adenocarcinoma of the colon or rectum;
Measurable disease or assessable but nonmeasurable disease allowed;
No prior oxaliplatin or bevacizumab.
No prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy allowed;
No prior fluoropyrimidine therapy (unless give in an adjuvant setting and completed at least 4 months earlier);
No bleeding diathesis or coagulopathy
Adequate renal and hepatic functions as per protocol;
Signed informed consent
Clinically significant cardiovascular or peripheral vascular disease;
Concurrent chronic aspirin, nonsteroidal anti-inflammatory drugs, warfarin, or therapeutic heparin;
Serious non-healing wound, ulcer, or bone fracture;